NASDAQ:SRGA

Surgalign Competitors

$2.05
-0.12 (-5.53 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.03
Now: $2.05
$2.19
50-Day Range
$2.10
MA: $2.38
$2.71
52-Week Range
$1.49
Now: $2.05
$3.97
Volume1.01 million shs
Average Volume1.95 million shs
Market Capitalization$226.05 million
P/E RatioN/A
Dividend YieldN/A
Beta2.21

Competitors

Surgalign (NASDAQ:SRGA) Vs. SIEN, IVC, SMTI, LAKE, CFMS, and RWLK

Should you be buying SRGA stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Surgalign, including Sientra (SIEN), Invacare (IVC), Sanara MedTech (SMTI), Lakeland Industries (LAKE), Conformis (CFMS), and ReWalk Robotics (RWLK).

Sientra (NASDAQ:SIEN) and Surgalign (NASDAQ:SRGA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Profitability

This table compares Sientra and Surgalign's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sientra-123.88%-174.05%-38.97%
Surgalign-56.07%-101.34%-18.44%

Volatility and Risk

Sientra has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Surgalign has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Sientra and Surgalign, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sientra00403.00
Surgalign00403.00

Sientra currently has a consensus price target of $10.00, indicating a potential upside of 39.47%. Surgalign has a consensus price target of $4.3333, indicating a potential upside of 111.38%. Given Surgalign's higher possible upside, analysts plainly believe Surgalign is more favorable than Sientra.

Insider & Institutional Ownership

71.0% of Sientra shares are held by institutional investors. Comparatively, 53.5% of Surgalign shares are held by institutional investors. 2.8% of Sientra shares are held by company insiders. Comparatively, 3.7% of Surgalign shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Sientra and Surgalign's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sientra$83.70 million4.91$-106,820,000.00($2.29)-3.13
Surgalign$308.38 million0.73$-211,640,000.00($0.16)-12.81

Sientra has higher earnings, but lower revenue than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than Sientra, indicating that it is currently the more affordable of the two stocks.

Summary

Surgalign beats Sientra on 9 of the 12 factors compared between the two stocks.

Surgalign (NASDAQ:SRGA) and Invacare (NYSE:IVC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Surgalign and Invacare, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Surgalign00403.00
Invacare00103.00

Surgalign currently has a consensus price target of $4.3333, indicating a potential upside of 111.38%. Invacare has a consensus price target of $17.00, indicating a potential upside of 105.56%. Given Surgalign's higher probable upside, equities analysts clearly believe Surgalign is more favorable than Invacare.

Institutional and Insider Ownership

53.5% of Surgalign shares are owned by institutional investors. Comparatively, 96.7% of Invacare shares are owned by institutional investors. 3.7% of Surgalign shares are owned by insiders. Comparatively, 3.2% of Invacare shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Surgalign and Invacare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Surgalign-56.07%-101.34%-18.44%
Invacare-4.87%-8.76%-3.07%

Volatility and Risk

Surgalign has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Invacare has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Earnings and Valuation

This table compares Surgalign and Invacare's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surgalign$308.38 million0.73$-211,640,000.00($0.16)-12.81
Invacare$927.96 million0.31$-53,330,000.00($1.06)-7.80

Invacare has higher revenue and earnings than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than Invacare, indicating that it is currently the more affordable of the two stocks.

Summary

Surgalign beats Invacare on 7 of the 13 factors compared between the two stocks.

Sanara MedTech (NASDAQ:SMTI) and Surgalign (NASDAQ:SRGA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Insider and Institutional Ownership

53.5% of Surgalign shares are held by institutional investors. 78.4% of Sanara MedTech shares are held by insiders. Comparatively, 3.7% of Surgalign shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sanara MedTech and Surgalign, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sanara MedTech0000N/A
Surgalign00403.00

Surgalign has a consensus target price of $4.3333, suggesting a potential upside of 111.38%. Given Surgalign's higher probable upside, analysts clearly believe Surgalign is more favorable than Sanara MedTech.

Profitability

This table compares Sanara MedTech and Surgalign's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sanara MedTech-39.58%-175.36%-55.40%
Surgalign-56.07%-101.34%-18.44%

Volatility and Risk

Sanara MedTech has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, Surgalign has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500.

Valuation & Earnings

This table compares Sanara MedTech and Surgalign's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sanara MedTech$11.77 million20.43$-2,810,000.00N/AN/A
Surgalign$308.38 million0.73$-211,640,000.00($0.16)-12.81

Sanara MedTech has higher earnings, but lower revenue than Surgalign.

Summary

Surgalign beats Sanara MedTech on 7 of the 12 factors compared between the two stocks.

Lakeland Industries (NASDAQ:LAKE) and Surgalign (NASDAQ:SRGA) are both small-cap industrial products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Profitability

This table compares Lakeland Industries and Surgalign's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lakeland Industries18.93%28.75%24.67%
Surgalign-56.07%-101.34%-18.44%

Analyst Ratings

This is a breakdown of current ratings and target prices for Lakeland Industries and Surgalign, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lakeland Industries00203.00
Surgalign00403.00

Lakeland Industries presently has a consensus price target of $31.3333, suggesting a potential upside of 11.59%. Surgalign has a consensus price target of $4.3333, suggesting a potential upside of 111.38%. Given Surgalign's higher possible upside, analysts plainly believe Surgalign is more favorable than Lakeland Industries.

Institutional & Insider Ownership

70.8% of Lakeland Industries shares are owned by institutional investors. Comparatively, 53.5% of Surgalign shares are owned by institutional investors. 4.9% of Lakeland Industries shares are owned by company insiders. Comparatively, 3.7% of Surgalign shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Lakeland Industries and Surgalign's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakeland Industries$107.81 million2.09$3.28 million$0.4562.40
Surgalign$308.38 million0.73$-211,640,000.00($0.16)-12.81

Lakeland Industries has higher earnings, but lower revenue than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than Lakeland Industries, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Lakeland Industries has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, Surgalign has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500.

Summary

Lakeland Industries beats Surgalign on 9 of the 13 factors compared between the two stocks.

Conformis (NASDAQ:CFMS) and Surgalign (NASDAQ:SRGA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Profitability

This table compares Conformis and Surgalign's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Conformis-32.11%-174.01%-32.59%
Surgalign-56.07%-101.34%-18.44%

Valuation & Earnings

This table compares Conformis and Surgalign's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conformis$77.43 million2.12$-28,480,000.00($0.44)-2.04
Surgalign$308.38 million0.73$-211,640,000.00($0.16)-12.81

Conformis has higher earnings, but lower revenue than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than Conformis, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

30.2% of Conformis shares are held by institutional investors. Comparatively, 53.5% of Surgalign shares are held by institutional investors. 3.2% of Conformis shares are held by insiders. Comparatively, 3.7% of Surgalign shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Conformis and Surgalign, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Conformis01302.75
Surgalign00403.00

Conformis presently has a consensus price target of $2.3333, indicating a potential upside of 160.07%. Surgalign has a consensus price target of $4.3333, indicating a potential upside of 111.38%. Given Conformis' higher probable upside, equities research analysts plainly believe Conformis is more favorable than Surgalign.

Risk & Volatility

Conformis has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Surgalign has a beta of 2.21, suggesting that its stock price is 121% more volatile than the S&P 500.

Summary

Surgalign beats Conformis on 10 of the 14 factors compared between the two stocks.

ReWalk Robotics (NASDAQ:RWLK) and Surgalign (NASDAQ:SRGA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares ReWalk Robotics and Surgalign's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ReWalk Robotics-312.35%-103.56%-55.24%
Surgalign-56.07%-101.34%-18.44%

Valuation and Earnings

This table compares ReWalk Robotics and Surgalign's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ReWalk Robotics$4.87 million20.16$-15,550,000.00($2.70)-0.79
Surgalign$308.38 million0.73$-211,640,000.00($0.16)-12.81

ReWalk Robotics has higher earnings, but lower revenue than Surgalign. Surgalign is trading at a lower price-to-earnings ratio than ReWalk Robotics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

1.5% of ReWalk Robotics shares are held by institutional investors. Comparatively, 53.5% of Surgalign shares are held by institutional investors. 6.9% of ReWalk Robotics shares are held by company insiders. Comparatively, 3.7% of Surgalign shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

ReWalk Robotics has a beta of 3.63, suggesting that its share price is 263% more volatile than the S&P 500. Comparatively, Surgalign has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for ReWalk Robotics and Surgalign, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ReWalk Robotics00103.00
Surgalign00403.00

ReWalk Robotics presently has a consensus target price of $3.50, suggesting a potential upside of 64.32%. Surgalign has a consensus target price of $4.3333, suggesting a potential upside of 111.38%. Given Surgalign's higher probable upside, analysts clearly believe Surgalign is more favorable than ReWalk Robotics.

Summary

Surgalign beats ReWalk Robotics on 9 of the 13 factors compared between the two stocks.


Surgalign Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sientra logo
SIEN
Sientra
1.6$7.17-2.4%$410.65 million$83.70 million-4.03
Invacare logo
IVC
Invacare
1.6$8.27-0.5%$284.69 million$927.96 million-6.72
SMTI
Sanara MedTech
0.8$31.57-1.4%$240.47 million$11.77 million-24.47
Lakeland Industries logo
LAKE
Lakeland Industries
1.6$28.08-0.2%$225.20 million$107.81 million7.98Upcoming Earnings
Conformis logo
CFMS
Conformis
1.3$0.90-0.1%$163.81 million$77.43 million-2.64
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.4$2.13-6.6%$98.18 million$4.87 million-1.69
CollPlant Biotechnologies logo
CLGN
CollPlant Biotechnologies
1.1$13.80-0.4%$78.25 million$2.32 million-6.90
Predictive Oncology logo
POAI
Predictive Oncology
1.3$1.49-5.4%$72.70 million$1.41 million-0.24High Trading Volume
Gap Down
AHPI
Allied Healthcare Products
0.5$4.58-3.5%$18.37 million$31.89 million0.00
NanoVibronix logo
NAOV
NanoVibronix
0.5$1.00-3.0%$13.39 million$530,000.00-1.67
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.